Endo, other drugmakers sued over ‘pay-for-delay’ deals


The Federal Trade Commission sued Endo Pharmaceuticals and several other drugmakers alleging that they used ‘pay-for-delay’ settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm. The agency alleges that Endo paid the first generic companies that wanted FDA approval – Impax Laboratories and Watson Laboratories